相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Non-Covalent Albumin Ligands in FDA-Approved Therapeutic Peptides and Proteins
Florencio Zaragoza
JOURNAL OF MEDICINAL CHEMISTRY (2023)
Albumin-binding DARPins as scaffold improve the hypoglycemic and anti-obesity effects of exendin-4 in vivo
Jinying Xia et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2023)
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis
Susanne Klint et al.
MABS (2023)
TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life
Emma Dave et al.
MABS (2023)
Serum albumin binding knob domains engineered within a VH framework III bispecific antibody format and as chimeric peptides
Ralph Adams et al.
FRONTIERS IN IMMUNOLOGY (2023)
Long-acting recombinant human follicle-stimulating hormone (SAFA-FSH) enhances spermatogenesis
Daham Kim et al.
FRONTIERS IN ENDOCRINOLOGY (2023)
Albumin-Binding Aptamer Chimeras for Improved siRNA Bioavailability
Jonah C. Rosch et al.
CELLULAR AND MOLECULAR BIOENGINEERING (2022)
Structure identification of circulating metabolites from somapacitan, a long-acting growth hormone derivative, and pharmacokinetics after single and multiple subcutaneous dosing in rats
Hans Helleberg et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2022)
Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3
Lars Savendahl et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)
Characterization of molecular interactions between cannabidiol and human plasma proteins (serum albumin and γ-globulin) by surface plasmon resonance, microcalorimetry, and molecular docking
Chang Liu et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2022)
Human and Mouse Cross-Reactive Albumin-Binding Helix-Loop- Helix Peptide Tag for Prolonged Bioactivity of Therapeutic Proteins
Yuto Nakatani et al.
MOLECULAR PHARMACEUTICS (2022)
Albumin binding Nanofitins, a new scaffold to extend half-life of biologics - a case study with exenatide peptide
Nadine Michot et al.
PEPTIDES (2022)
IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY
F. Behrens et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies
Hanine Rafidi et al.
MABS (2022)
Ozoralizumab for rheumatoid arthritis
Jennifer Thorley
LANCET RHEUMATOLOGY (2022)
Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis
Tsutomu Takeuchi et al.
ARTHRITIS & RHEUMATOLOGY (2022)
Albumin-binding domain extends half-life of glucagon-like peptide-1
Huanbo Tan et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Prediction of Half-Life Extension of Peptides via Serum Albumin Binding: Current Challenges
Youssef Hijazi
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2021)
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
Richard D. Baird et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Small Bispecific Affinity Proteins for Simultaneous Target Binding and Albumin-Associated Half-Life Extension
Emma von Witting et al.
MOLECULAR PHARMACEUTICS (2021)
APB-F1, a long-acting feline granulocyte colony-stimulating factor fusion protein, created by exploiting FL335, a chimeric Fab specific for feline serum albumin
Hyun-jin Chi et al.
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY (2021)
Integrative proteomics identifies thousands of distinct, multi-epitope, and high-affinity nanobodies
Yufei Xiang et al.
CELL SYSTEMS (2021)
IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study
Kim A Papp et al.
LANCET (2021)
The Uniqueness of Albumin as a Carrier in Nanodrug Delivery
Alessandra Spada et al.
MOLECULAR PHARMACEUTICS (2021)
Protein Engineering Strategies for Improved Pharmacokinetics
Aurelie Rondon et al.
ADVANCED FUNCTIONAL MATERIALS (2021)
Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain
Qingbin Zhang et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
A phase II trial combining tumortargeting TP53 gene therapy with gemcitabine/nab-paclitaxel as a second-line treatment for metastatic pancreatic cancer.
Chris Poki Leung et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics
Xiaotian Zhong et al.
ANTIBODIES (2021)
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
Simone Mester et al.
MABS (2021)
Site-specific bioconjugation and self-assembly technologies for multi-functional biologics: on the road to the clinic
Sung In Lim
DRUG DISCOVERY TODAY (2020)
VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis
Sarah Low et al.
MABS (2020)
Serum albumin-binding VHHs with variable pH sensitivities enable tailored half-life extension of biologics
Henk van Faassen et al.
FASEB JOURNAL (2020)
Intramolecular distance in the conjugate of urate oxidase and fatty acid governs FcRn binding and serum half-life in vivo
Jinhwan Cho et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Affimers as an alternative to antibodies for protein biomarker enrichment
Roel Tans et al.
PROTEIN EXPRESSION AND PURIFICATION (2020)
Recombinant Peptide Production Platform Coupled with Site-Specific Albumin Conjugation Enables a Convenient Production of Long-Acting Therapeutic Peptide
Mijeong Bak et al.
PHARMACEUTICS (2020)
Fine-tuning bispecific therapeutics
Sung In Lim
PHARMACOLOGY & THERAPEUTICS (2020)
Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment
Rena Liu et al.
ANTIBODIES (2020)
Intact bioactivities and improved pharmacokinetic of the SL335-IFN-β-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-β
Soo-In Ji et al.
IMMUNOLOGY LETTERS (2019)
Fusion with an albumin-binding domain improves pharmacokinetics of an αvβ3-integrin binding fibronectin scaffold protein
S. Sh. Gapizov et al.
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY (2019)
Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics
Alessandro Zorzi et al.
MEDCHEMCOMM (2019)
Extending Half Life of H-Ferritin Nanoparticle by Fusing Albumin Binding Domain for Doxorubicin Encapsulation
Chunyue Wang et al.
BIOMACROMOLECULES (2018)
Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Huanbo Tan et al.
CURRENT PHARMACEUTICAL DESIGN (2018)
Human and mouse albumin bind their respective neonatal Fc receptors differently
Jeannette Nilsen et al.
SCIENTIFIC REPORTS (2018)
Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone
Peter Thygesen et al.
GROWTH HORMONE & IGF RESEARCH (2017)
Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin
Esben G. W. Schmidt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins
Catia Cantante et al.
JOURNAL OF BIOTECHNOLOGY (2017)
An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide
Daejin Kim et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Development of DNA Nanostructures for High-Affinity Binding to Human Serum Albumin
Auraelie Lacroix et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2017)
Albumin Binding Domain Fusing R/K-X-X-R/K Sequence for Enhancing Tumor Delivery of Doxorubicin
Liping Liu et al.
MOLECULAR PHARMACEUTICS (2017)
Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing
Samantha M. Sarett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Half-life extension using serum albumin-binding DARPin (R) domains
Daniel Steiner et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2017)
Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides
Alessandro Zorzi et al.
NATURE COMMUNICATIONS (2017)
MP0250, a VEGF and HGF neutralizing DARPin® molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models
Ulrike Fiedler et al.
ONCOTARGET (2017)
Isolation of human anti-serum albumin Fab antibodies with an extended serum-half life
Hyeon-Ju Kang et al.
IMMUNOLOGY LETTERS (2016)
Fusion of an albumin-binding domain extends the half-life of immunotoxins
Rui Guo et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL
Rui Li et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding
Emma Dave et al.
MABS (2016)
Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life
Ralph Adams et al.
MABS (2016)
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
Jesper Lau et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics
Steven A. Jacobs et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2015)
GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans-PK/PD and Safety
R. L. O'Connor-Semmes et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Dissection of the Neonatal Fc Receptor (FcRn)-Albumin Interface Using Mutagenesis and Anti-FcRn Albumin-blocking Antibodies
Kine Marita Knudsen Sand et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Interaction with Both Domain I and III of Albumin Is Required for Optimal pH-dependent Binding to the Neonatal Fc Receptor (FcRn)
Kine Marita Knudsen Sand et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Extending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor ( FcRn) Binding
Jan Terje Andersen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Synthetic cationic antimicrobial peptides bind with their hydrophobic parts to drug site II of human serum albumin
Annfrid Sivertsen et al.
BMC STRUCTURAL BIOLOGY (2014)
Albumin as a versatile platform for drug half-life extension
Darrell Sleep et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2013)
Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat
Weike Bao et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein
Anna Orlova et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society December 3-6, 2012, San Diego, CA
Peter-Christian Kloehn et al.
MABS (2013)
Crystal Structure of an HSA/FcRn Complex Reveals Recycling by Competitive Mimicry of HSA Ligands at a pH-Dependent Hydrophobic Interface
Michael M. Schmidt et al.
STRUCTURE (2013)
Amino-Modified and Lipid-Conjugated Dicer-Substrate siRNA Enhances RNAi Efficacy
Takanori Kubo et al.
BIOCONJUGATE CHEMISTRY (2012)
Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain
Mischa R. Mueller et al.
MABS (2012)
Engineering Bispecificity into a Single Albumin-Binding Domain
Johan Nilvebrant et al.
PLOS ONE (2011)
Albumin-Binding and Angiogenic Domains of SPARC Located at Its C-Terminus.
D. Knauer et al.
CANCER RESEARCH (2010)
Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding
Jan Terje Andersen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Aptamers as therapeutics
Anthony D. Keefe et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein
Jonas Hopp et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Engineered protein scaffolds as next-generation antibody therapeutics
Michaela Gebauer et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2009)
Self-Assembly of Ibuprofen and Bovine Serum Albumin-Dextran Conjugates Leading to Effective Loading of the Drug
Juan Li et al.
LANGMUIR (2009)
Identification of high affinity fatty acid binding sites on human serum albumin by MM-PBSA method
Shin-Ichi Fujiwara et al.
BIOPHYSICAL JOURNAL (2008)
Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology
Bernard M. Tijink et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs
Lucy J. Holt et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2008)
Engineering of a femtomolar affinity binding protein to human serum albumin
Andreas Jonsson et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2008)
A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G
Roland Stork et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2007)
Preparation and characterization of a potent, long-lasting recombinant human serum albumin-interferon-α2b fusion protein expressed in Pichia pastoris
Yan-Shan Huang et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2007)
An artificially evolved albumin binding module facilitates chemical shift epitope mapping of GA domain interactions with phylogenetically diverse albumins
Yanan He et al.
PROTEIN SCIENCE (2007)
The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin
Allen Nguyen et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2006)
Engineered antibody fragments and the rise of single domains
P Holliger et al.
NATURE BIOTECHNOLOGY (2005)
Aggregation-resistant domain antibodies selected on phage by heat denaturation
L Jespers et al.
NATURE BIOTECHNOLOGY (2004)
Albumin binding as a general strategy for improving the pharmacokinetics of proteins
MS Dennis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Structure, specificity, and mode of interaction for bacterial albumin-binding modules
MU Johansson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Stability towards alkaline conditions can be engineered into a protein ligand
S Gülich et al.
JOURNAL OF BIOTECHNOLOGY (2000)